Skip to main content
112kviews
Editorial19 February 2021
Editorial: The Biological and Clinical Aspects of HLA-G

In this Research Topic, we hosted eight in-depth reviews, minireviews, and original research articles on the biological and clinical aspects of HLA-G. This could be unattainable without the enthusiastic involvement of all contributing authors, participating reviewers and the assistance from the staff of Frontiers in Immunology.HLA-G belongs to the non-classical HLA class I family. HLA-G features limited genetic variation, very restricted tissue expression, and immune tolerogenic functions, being a ligand of immune inhibitory receptors. HLA-G is now recognized as an important immune checkpoint.

HLA-G1~HLA-G4; soluble isoforms:HLA-G5~HLA-G7), can be generated due to its primary transcript alternative splicing. Since HLA-G gene had been identified in 1987 (1) and HLA-G protein expression first observed in extravillious cytotrophoblasts in 1990 (2) In summary, this special issue highlights the current advances regarding the biological and clinical importance of HLA-G in various physio-phatological situations. Undoubtedly, HLA-G is a promising biomarker and therapeutic target for different diseases, even though isoform-specific antibodies are still lacking, which prevents advances in characterizing their clinical significance.

YWH wrote the first draft of the manuscript and updated the last version.JLM corrected the draft.

3,098 views

11 citations

During pregnancy, the maternal uterus and fetus form a special microenvironment at the maternal-fetal interface to support the development of the fetus. Extravillous trophoblasts (EVTs), differentiated from the fetus, invade into decidua and interact with maternal cells. Human leukocyte antigen (HLA)-G is a non-classical MHC-I molecule that is expressed abundantly and specifically on EVTs in physiological conditions. Soluble HLA-G (sHLA-G) is also found in maternal blood, amniotic fluid and cord blood. The abnormal expression and polymorphisms of HLA-G are related to adverse pregnancy outcomes such as preeclampsia (PE) and recurrent spontaneous abortion (RSA). Here we summarize current findings about three main roles of HLA-G during pregnancy, namely its promotion of spiral artery remodeling, immune tolerance, and fetal growth, all resulting from its interaction with immune cells. These findings are not only of great significance for the treatment of pregnancy-related diseases, but also provide clues for tumor immunology research since HLA-G functions as a checkpoint in tumors.

28,250 views

177 citations

HLA-G is a HLA class Ib antigen that possesses immunomodulatory properties. HLA-G+CD4+, HLA-G+CD8+ and HLA-G+CD4+ regulatory T cells with immune-suppressive and immunoregulatory functions are present in small amounts in physiologic conditions. Increased amounts of these HLA-G positive cells have been detected in several immune mediated diseases, like multiple sclerosis, psoriasis, systemic lupus erythematosus and systemic sclerosis. Further investigations are required in order to define a possible role of HLA-G positive immune cells in the pathogenesis of immune mediated diseases.

12,498 views

80 citations

ORIGINAL RESEARCH
19 November 2020
Intratumor Heterogeneity of HLA-G Expression in Cancer Lesions
Xia Zhang, 8 more and Wei-Hua Yan

4,130 views

14 citations

REVIEW
14 August 2020
HLA-G Neo-Expression on Tumors
Maria Loustau, 4 more and Julien Caumartin
HLA-G Neo-Expression on Tumors
HLA-G is known to modulate the immune system activity in tissues where physiological immune-tolerance is necessary (i.e. maternal-fetal interface, thymus and cornea). However, the frequent neo-expression of HLA-G in many cancer types has been previously and extensively described and is correlated with a bad prognosis. Despite being an MHC class I molecule, HLA-G is highly present in tumor context and shows unique characteristics of tissue restriction of a Tumor Associated Antigen (TAA) and potent immunosuppressive activity of an Immune CheckPoint (ICP). Consequently, HLA-G appears to be an excellent molecular target for immunotherapy. Although the relevance of HLA-G in cancer incidence and development has been proven in numerous tumors, its neo-expression pattern is still difficult to determine. Indeed, the estimation of HLA-G’s actual expression in tumor tissue is limited, particularly concerning the presence and percentage of the new non-canonical isoforms, for which detection antibodies are scarce or inexistent. Here, we summarize the current knowledge about HLA-G neo-expression and implication in various tumor types, pointing out the need for the development of new tools to analyze in-depth the HLA-G neo-expression patterns, opening the way for the generation of new monoclonal antibodies and cell-based immunotherapies.

17,660 views

81 citations